From the bench to the bedside: ways to improve rituximab efficacy.
about
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsBiologics in dermatology: an integrated reviewTreatment of diffuse large B cell lymphomaNew antibody approaches to lymphoma therapyDynamics of macrophage trogocytosis of rituximab-coated B cellsTargeting NF-kappaB in Waldenstrom macroglobulinemiaDenileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disordersImmunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusionMechanisms of action of therapeutic antibodies for cancerStatins impair antitumor effects of rituximab by inducing conformational changes of CD20Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular LymphomaExhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsRituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.Clinical utility of rituximab in chronic graft-versus-host disease.Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesEfficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature reviewRituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMabRituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphomaRecombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primatesAggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stressIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityPopulation pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcomeTherapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysRelevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.Regulation of CD20 expression by radiation-induced changes in intracellular redox status.FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.Monoclonal antibodies: versatile platforms for cancer immunotherapy.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaHighly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
P2860
Q26751002-CB858E56-DC67-4769-AD3E-D10CE5D712F4Q26768154-A5E76E07-FD84-44C9-8EF3-A91C0259DABEQ26849243-69942FF6-84FB-4A6E-A681-DCA4DE738650Q27004638-9B9AD97B-6F60-4625-A1FB-9F7A12394A45Q27006062-870DD974-5AF7-4BAF-96FE-9F1E28574E56Q27022373-FDD0B814-468D-4C62-83BD-87E15DF5390EQ27314806-7807B704-9C36-4FAB-B941-8AAEE0C0F5D0Q28272373-7108D3D8-5E27-4F29-A018-D039B88DB88EQ28280510-37C8B1BD-60C8-4FA2-B461-ECA1B453D9BFQ28296706-2879167E-CAE0-4174-8157-FD8E2F5E31D3Q28385366-352A75BF-F1F2-41D6-AE7D-32A2FFC8C2F4Q28472420-D594B418-B8CB-4D65-88A3-2AE1625A2627Q30278460-F7758CEA-1756-4F1E-B071-F5847C2FA2A0Q30421637-03550A35-6F76-44A1-AF3F-F14BAE6CC79AQ31032919-64E8E7A1-C3E1-44ED-831B-353D173087F6Q33224048-54AE17AC-821F-44DD-A8F1-4FDBF233E06EQ33378309-3D678900-EDB2-4752-9540-B5A95A3817A1Q33383124-B795CBD0-EA38-4951-991A-7AC753E4764EQ33389752-B8C765D0-2949-46DD-A030-0B883A7E3262Q33402453-602F4F5B-2592-4659-A082-94ED271FA241Q33407700-D4077A46-01D2-454A-9F66-C7012B125F56Q33422543-FCB6A5DD-E417-4564-94E2-ECEB799C0082Q33435662-EF54D627-93C7-42B6-8F99-CE609CD40E39Q33437682-4C8338B8-20BA-4283-9ECA-8C2EFA6F9C93Q33573605-47806AEE-40CE-48AB-A23B-CFE230C335D2Q33599174-E9C803C0-830F-4CA2-9AE7-7CCB2A6CC1B9Q33781006-DA8E2DE4-BB65-492A-BA34-3CDDE02870B4Q33788697-C791825E-2A32-47E6-B7A6-56C53283185EQ33822191-F53D2437-AB69-4EBF-A6B4-CA1FB60D9B51Q33834215-C0DBB21A-D3C4-4C20-A463-95A353E22B80Q33896738-97CE61A1-E735-403F-839D-842B677D52DEQ33903709-B14841A5-5767-4645-BBCD-6FF8CE30FD0AQ33944243-973C345F-03F6-4554-850E-19BBA891F661Q33971785-530E9A00-D748-4722-8A44-71AF6DC0E635Q34050433-9BF908ED-1E7B-4BBE-B2D6-A5CC2BE444AAQ34088194-124F2278-2E0B-4316-94B9-698C3E5A529AQ34111693-530F9E7A-C81A-4A46-A854-2BEB4593DB59Q34144940-0E3427FE-F6AE-43B0-9C12-CBBEC5809BBAQ34223872-57BE7C54-D013-4D86-B97F-DDCD63EB056DQ34231085-4C2E2625-F500-4872-B412-BB00765443E8
P2860
From the bench to the bedside: ways to improve rituximab efficacy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
From the bench to the bedside: ways to improve rituximab efficacy.
@ast
From the bench to the bedside: ways to improve rituximab efficacy.
@en
type
label
From the bench to the bedside: ways to improve rituximab efficacy.
@ast
From the bench to the bedside: ways to improve rituximab efficacy.
@en
prefLabel
From the bench to the bedside: ways to improve rituximab efficacy.
@ast
From the bench to the bedside: ways to improve rituximab efficacy.
@en
P1433
P1476
From the bench to the bedside: ways to improve rituximab efficacy
@en
P2093
Hervé Watier
Philippe Solal-Celigny
P304
P356
10.1182/BLOOD-2004-03-1110
P407
P577
2004-06-29T00:00:00Z